The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone

Sun Ok Song, Kwang Joon Kim, Byung Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitaz. This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics. Methods: Th retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder cancerwho presented at theSeverance Hospital from November 2005 to June 2011. The control group consisted of patients without bladder cancer (1:2 ratio mtchin for sex and age, n=658) who were listed on the Severance Hospital diabetes registry. Results: The percentage of subjects who had eve used pioglitazone was significantly lower in the case group than in the control group (6.4% vs. 15.0%, P<0.001). Multivaria onditional logistic analysis revealed that independent factors affecting bladder cancer were smoking (odds ratio [OR], 11.64; 95% cofidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95% CI, 2.25 to 16.63; P<0.001), and hemoglobin levels OR, 0.78; 95% CI, 0.69 to 0.88; P<0.001). The OR of the history of pioglitazoneuse was 2.09 and was not significantly different between the two groups (95% CI, 0.26 to 16.81; P=0.488). Conclusion: A relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic patients.This suggests that the risk for bladder cancer in Korean diabetic subjects treated ith pioglitazone might be different from that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.

Original languageEnglish
Pages (from-to)371-378
Number of pages8
JournalDiabetes and Metabolism Journal
Volume36
Issue number5
DOIs
Publication statusPublished - 2012 Oct 1

Fingerprint

pioglitazone
Urinary Bladder Neoplasms
Odds Ratio
Control Groups
Incidence
Sex Ratio
Registries
Case-Control Studies
Hemoglobins
Urinary Bladder
Smoking
History

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Song, Sun Ok ; Kim, Kwang Joon ; Lee, Byung Wan ; Kang, Eun Seok ; Cha, Bong Soo ; Lee, Hyun Chul. / The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. In: Diabetes and Metabolism Journal. 2012 ; Vol. 36, No. 5. pp. 371-378.
@article{bbf0b9e692174478a6b54dbcbbbece2a,
title = "The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone",
abstract = "Background: There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitaz. This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics. Methods: Th retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder cancerwho presented at theSeverance Hospital from November 2005 to June 2011. The control group consisted of patients without bladder cancer (1:2 ratio mtchin for sex and age, n=658) who were listed on the Severance Hospital diabetes registry. Results: The percentage of subjects who had eve used pioglitazone was significantly lower in the case group than in the control group (6.4{\%} vs. 15.0{\%}, P<0.001). Multivaria onditional logistic analysis revealed that independent factors affecting bladder cancer were smoking (odds ratio [OR], 11.64; 95{\%} cofidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95{\%} CI, 2.25 to 16.63; P<0.001), and hemoglobin levels OR, 0.78; 95{\%} CI, 0.69 to 0.88; P<0.001). The OR of the history of pioglitazoneuse was 2.09 and was not significantly different between the two groups (95{\%} CI, 0.26 to 16.81; P=0.488). Conclusion: A relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic patients.This suggests that the risk for bladder cancer in Korean diabetic subjects treated ith pioglitazone might be different from that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.",
author = "Song, {Sun Ok} and Kim, {Kwang Joon} and Lee, {Byung Wan} and Kang, {Eun Seok} and Cha, {Bong Soo} and Lee, {Hyun Chul}",
year = "2012",
month = "10",
day = "1",
doi = "10.4093/dmj.2012.36.5.371",
language = "English",
volume = "36",
pages = "371--378",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "5",

}

The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. / Song, Sun Ok; Kim, Kwang Joon; Lee, Byung Wan; Kang, Eun Seok; Cha, Bong Soo; Lee, Hyun Chul.

In: Diabetes and Metabolism Journal, Vol. 36, No. 5, 01.10.2012, p. 371-378.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone

AU - Song, Sun Ok

AU - Kim, Kwang Joon

AU - Lee, Byung Wan

AU - Kang, Eun Seok

AU - Cha, Bong Soo

AU - Lee, Hyun Chul

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background: There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitaz. This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics. Methods: Th retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder cancerwho presented at theSeverance Hospital from November 2005 to June 2011. The control group consisted of patients without bladder cancer (1:2 ratio mtchin for sex and age, n=658) who were listed on the Severance Hospital diabetes registry. Results: The percentage of subjects who had eve used pioglitazone was significantly lower in the case group than in the control group (6.4% vs. 15.0%, P<0.001). Multivaria onditional logistic analysis revealed that independent factors affecting bladder cancer were smoking (odds ratio [OR], 11.64; 95% cofidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95% CI, 2.25 to 16.63; P<0.001), and hemoglobin levels OR, 0.78; 95% CI, 0.69 to 0.88; P<0.001). The OR of the history of pioglitazoneuse was 2.09 and was not significantly different between the two groups (95% CI, 0.26 to 16.81; P=0.488). Conclusion: A relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic patients.This suggests that the risk for bladder cancer in Korean diabetic subjects treated ith pioglitazone might be different from that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.

AB - Background: There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitaz. This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics. Methods: Th retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder cancerwho presented at theSeverance Hospital from November 2005 to June 2011. The control group consisted of patients without bladder cancer (1:2 ratio mtchin for sex and age, n=658) who were listed on the Severance Hospital diabetes registry. Results: The percentage of subjects who had eve used pioglitazone was significantly lower in the case group than in the control group (6.4% vs. 15.0%, P<0.001). Multivaria onditional logistic analysis revealed that independent factors affecting bladder cancer were smoking (odds ratio [OR], 11.64; 95% cofidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95% CI, 2.25 to 16.63; P<0.001), and hemoglobin levels OR, 0.78; 95% CI, 0.69 to 0.88; P<0.001). The OR of the history of pioglitazoneuse was 2.09 and was not significantly different between the two groups (95% CI, 0.26 to 16.81; P=0.488). Conclusion: A relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic patients.This suggests that the risk for bladder cancer in Korean diabetic subjects treated ith pioglitazone might be different from that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.

UR - http://www.scopus.com/inward/record.url?scp=84870268099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870268099&partnerID=8YFLogxK

U2 - 10.4093/dmj.2012.36.5.371

DO - 10.4093/dmj.2012.36.5.371

M3 - Article

C2 - 23130322

AN - SCOPUS:84870268099

VL - 36

SP - 371

EP - 378

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 5

ER -